%20scale(0.100000,-0.100000)'%20fill='%23000000'%20stroke='none'%3e%3cpath%20d='M3195%205489%20c-380%20-49%20-706%20-317%20-831%20-682%20-56%20-163%20-54%20-112%20-54%20-1773%20l0%20-1534%20590%200%20590%200%200%201465%200%201465%20600%200%20600%200%200%20535%200%20535%20-712%20-1%20c-392%20-1%20-744%20-6%20-783%20-10z'/%3e%3c/g%3e%3c/svg%3e)
Roivant Sciences
ROIV· Manufacturing· Fiscal year ends in March
Matthew Gline is the CEO of Roivant Sciences and was paid $163.3M in FY2024 (Mar), up 22,021%.
Executives6
See all- 1Mayukh SukhatmePresident and Chief Investment OfficerFY2024
- 2Matthew GlineChief Executive OfficerFY2024
- 3Eric VenkerPresident and Immunovant CEOFY2024
- 4Rakhi KumarFormer Chief Accounting OfficerFY2024
- 5Richard PulikChief Financial OfficerFY2024
- 6Jennifer HumesChief Accounting OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allRoivant Sciences paid its 6 named executives $438.2M in total in FY2024 (Mar). CEO Eric Venker was paid $11.8M of that.
| Name | |||
|---|---|---|---|
| Mayukh SukhatmePresident and Chief Investment Officer | |||
| Matthew GlineChief Executive Officer | |||
| Eric VenkerPresident and Immunovant CEO | Not disclosed | ||
| Rakhi KumarFormer Chief Accounting Officer | Not disclosed | ||
| Richard PulikChief Financial Officer | Not disclosed | ||
| Jennifer HumesChief Accounting Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers25
See allThe FY2024 (Mar) proxy of Roivant Sciences names 25 peer companies for pay. Among Roivant Sciences and these peers, CEO pay was the highest of 9 and total shareholder return was 3rd highest of 9.
1st highest of 9in Roivant Sciences and its pay peers, FY2024 (Mar) by CEO pay:
3rd highest of 9in Roivant Sciences and its pay peers, FY2024 (Mar) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board5
See all- Ilan OrenChair · 10 yr on the boardIndependentCompensation, Nominating and Governance (Chair)—Paid as an executive
- Keith ManchesterDirector · 10 yr on the boardIndependentAudit—Paid as an executive
- James C. MomtazeeDirector · 3 yr on the boardIndependentNominating and Governance—Paid as an executive
- Melissa EpperlyDirector · 2 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Mayukh SukhatmeDirector · 1 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Jul 29, 2025 | FY2024 |
| Annual report | 10-K | May 29, 2025 | FY2025 |
| Proxy statement | DEF 14A | Jul 26, 2024 | FY2023 |
| Annual report | 10-K | May 30, 2024 | FY2024 |
| Proxy statement | DEF 14A | Jul 31, 2023 | FY2022 |
| Annual report | 10-K | Jun 28, 2023 | FY2023 |
